Open Access Articles- Top Results for Dinapsoline


File:Dinapsoline structure.png
Systematic (IUPAC) name
Clinical data
458563-40-1 7pxY
PubChem CID 9816455
ChemSpider 7992205 7pxN
Chemical data
Formula C16H15NO2
253.295 g/mol
 14pxN (what is this?)  (verify)

Dinapsoline is a drug developed for the treatment of Parkinson's disease,[1] that acts as a selective full agonist at the dopamine D1 receptor.[2][3][4][5]


  1. ^ Gulwadi AG, Korpinen CD, Mailman RB, Nichols DE, Sit SY, Taber MT (February 2001). "Dinapsoline: characterization of a D1 dopamine receptor agonist in a rat model of Parkinson's disease". The Journal of Pharmacology and Experimental Therapeutics 296 (2): 338–44. PMID 11160615. 
  2. ^ Ghosh D, Snyder SE, Watts VJ, Mailman RB, Nichols DE (January 1996). "9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline: a potent full dopamine D1 agonist containing a rigid-beta-phenyldopamine pharmacophore". Journal of Medicinal Chemistry 39 (2): 549–55. PMID 8558526. doi:10.1021/jm950707. 
  3. ^ Sit SY, Xie K, Jacutin-Porte S, Taber MT, Gulwadi AG, Korpinen CD, Burris KD, Molski TF, Ryan E, Xu C, Wong H, Zhu J, Krishnananthan S, Gao Q, Verdoorn T, Johnson G (August 2002). "(+)-Dinapsoline: an efficient synthesis and pharmacological profile of a novel dopamine agonist". Journal of Medicinal Chemistry 45 (17): 3660–8. PMID 12166939. doi:10.1021/jm0101545. 
  4. ^ Sit SY, Xie K, Jacutin-Porte S, Boy KM, Seanz J, Taber MT, Gulwadi AG, Korpinen CD, Burris KD, Molski TF, Ryan E, Xu C, Verdoorn T, Johnson G, Nichols DE, Mailman RB (February 2004). "Synthesis and SAR exploration of dinapsoline analogues". Bioorg. Med. Chem. 12 (4): 715–34. PMID 14759732. doi:10.1016/j.bmc.2003.11.015. 
  5. ^ Gleason SD, Witkin JM (May 2006). "Effects of dopamine D1 receptor agonists in rats trained to discriminate dihydrexidine". Psychopharmacology (Berl.) 186 (1): 25–31. PMID 16575553. doi:10.1007/s00213-006-0342-2. 

Lua error in package.lua at line 80: module 'Module:Buffer' not found.